Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Til Menge

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Archives of Neurology|February 11, 2009
Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosisOlaf Stüve, Verena I Leussink, Ruth Fröhlich, et al.
Archives of Neurology|November 16, 2005
Acute disseminated encephalomyelitis: an updateTil Menge, Bernhard Hemmer, Stefan Nessler, et al.
Archives of Neurology|October 13, 2010
Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis opticaSudhakar Reddy Kalluri, Zsolt Illes, Rajneesh Srivastava, et al.
Current Pharmaceutical Design|January 11, 2012
Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effectsMartin S Weber, Til Menge, Klaus Lehmann-Horn, et al.
Archives of Neurology|September 15, 2010
Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon betaAjith Sominanda, Malin Lundkvist, Anna Fogdell-Hahn, et al.
Journal of Alzheimer'S Disease : JAD|November 6, 2019
Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's DiseaseJulia Christl, Sandra Verhülsdonk, Francesca Pessanha, et al.
Expert Review of Neurotherapeutics|March 25, 2015
Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safetyDuvyanshu Dubey, Bernd C Kieseier, Hans P Hartung, et al.
Archives of Neurology|July 14, 2010
Natalizumab treatment in a patient with chronic inflammatory demyelinating polyneuropathyChristian Wolf, Til Menge, Max-Philipp Stenner, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 8, 2006
Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosisPatrice H Lalive, Til Menge, Cecile Delarasse, et al.
Annals of Neurology|July 15, 2020
Normal Pressure Hydrocephalus Associated with Alzheimer's DiseaseKatharina Müller-Schmitz, Natalia Krasavina-Loka, Tugba Yardimci, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Archives of Neurology|February 11, 2009
Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosisOlaf Stüve, Verena I Leussink, Ruth Fröhlich, et al.
Archives of Neurology|November 16, 2005
Acute disseminated encephalomyelitis: an updateTil Menge, Bernhard Hemmer, Stefan Nessler, et al.
Archives of Neurology|October 13, 2010
Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis opticaSudhakar Reddy Kalluri, Zsolt Illes, Rajneesh Srivastava, et al.
Current Pharmaceutical Design|January 11, 2012
Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effectsMartin S Weber, Til Menge, Klaus Lehmann-Horn, et al.
Archives of Neurology|September 15, 2010
Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon betaAjith Sominanda, Malin Lundkvist, Anna Fogdell-Hahn, et al.
Journal of Alzheimer'S Disease : JAD|November 6, 2019
Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's DiseaseJulia Christl, Sandra Verhülsdonk, Francesca Pessanha, et al.
Expert Review of Neurotherapeutics|March 25, 2015
Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safetyDuvyanshu Dubey, Bernd C Kieseier, Hans P Hartung, et al.
Archives of Neurology|July 14, 2010
Natalizumab treatment in a patient with chronic inflammatory demyelinating polyneuropathyChristian Wolf, Til Menge, Max-Philipp Stenner, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 8, 2006
Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosisPatrice H Lalive, Til Menge, Cecile Delarasse, et al.
Annals of Neurology|July 15, 2020
Normal Pressure Hydrocephalus Associated with Alzheimer's DiseaseKatharina Müller-Schmitz, Natalia Krasavina-Loka, Tugba Yardimci, et al.
Pageof 5